Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307712 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mi Na Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B virus, Virus Replication. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Antiviral therapy (AVT) is required in patients with newly diagnosed hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), if HBV DNA is detectable. We compared the risk of recurrence according to HBV replication activity at the curative treatment of HBV-related HCC.
Methods
Patients with HBV-related HCC who underwent surgical resection or radiofrequency ablation between 2013 and 2018 were enrolled in this retrospective cohort study. Patients were categorized into two groups according to HBV replication activity at the curative treatment of HBV-related HCC (group 1: patients who met the AVT indication for HBV-related HCC due to detectable HBV DNA but did not meet the AVT indication if without HCC; group 2: patients who met the AVT indication, regardless of HCC).
Results
In the entire cohort (n = 911), HCC recurred in 303 (33.3%) patients during a median follow-up of 4.7 years. After multivariate adjustment, group 2 showed a statistically similar risk of HCC recurrence (adjusted hazard ratio [aHR] = 1.18, P = 0.332) compared to that of group 1. In addition, group 2 showed statistically similar risks of early (< 2 years; aHR = 1.31) and late (≥ 2 years; aHR = 0.83) recurrence than that of group 1 (all P >0.05). Propensity score matching and inverse probability of treatment weighting analysis also yielded similar risks of HCC recurrence between the two groups (all P >0.05, log-rank tests).
Conclusions
The risk of HCC recurrence in patients who received curative treatment for newly diagnosed HBV-related HCC was similar regardless of HBV replication activity, if AVT was properly initiated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Seung Up Kim
Zitieren
APA
Kim, M. N., Kim, B. K., Cho, H., Goh, M. J., Roh, Y. H., Yu, S. J., Sinn, D. H., Park, S. Y., & Kim, S. U. (2024). Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity. PLOS ONE. https://doi.org/10.1371/journal.pone.0307712
Vancouver
Kim MN, Kim BK, Cho H, Goh MJ, Roh YH, Yu SJ, et al. Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity. PLOS ONE. 2024. doi:10.1371/journal.pone.0307712
BibTeX
@article{Kim2024,
author = {Kim, Mi Na and Kim, Beom Kyung and Cho, Heejin and Goh, Myung Ji and Roh, Yun Ho and Yu, Su Jong and Sinn, Dong Hyun and Park, Soo Young and Kim, Seung Up},
title = {Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307712}
}
EUVIMED